SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
–Â Neuroendocrine Prostate Cancer is Growing Unmet Medical Need – NEW YORK, Aug. 24, 2022 (GLOBE…